Aduro Biotech Europe’s Hans van Eenennaam, Ph.D. and John

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aduro Biotech Europe’s Hans van Eenennaam, Ph.D. and John Dulos, Ph.D. Honored with the Intellectual Property Owners Education Foundation’s 43rd Inventor of the Year Award for Contributions in the Discovery of KEYTRUDA® (pembrolizumab)

BERKELEY, Calif. and OSS, The Netherlands, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO ), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that Hans van Eenennaam, Ph.D., chief operational officer and executive director of Aduro Biotech Europe, and John Dulos, Ph.D., principal scientist, will be honored tonight by the Intellectual Property Owners Education Foundation (IPOEF) as winners of the 43rd Inventor of the Year Award for their work relating to the discovery of KEYTRUDA ® (pembrolizumab). KEYTRUDA is marketed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the U.S. and Canada) and is the first FDA-approved PD-1 inhibitor for the treatment of select cancers.

“It is an honor to have been part of the team whose work led to the discovery of KEYTRUDA and positively impacted the lives of many cancer patients,” said Dr. van Eenennaam. “Now as part of Aduro Biotech Europe, where we are focused on developing novel B-select antibodies to modulate the immune system, we are pleased to be collaborating once again with the MSD team on what we believe to be the best-in-class anti-CD27 therapeutic antibody.”

Dr. Dulos, principal scientist and project team lead for Aduro’s anti-APRIL BION-1301 program, commented, “As a scientist, it is incredibly satisfying to have been part of a team whose discoveries today are having a meaningful impact on the lives of many patients with several cancer types.  We thank the Intellectual Property Owners Education Foundation for this honor and will continue to leverage our knowledge and discoveries in the field of immuno-oncology with the aim of helping cancer patients in need.”

Hans van Eenennaam, Ph.D., a chemist by training, has nearly 15 years of experience in the pharmaceutical and biotechnology industry and in-depth expertise in the field of immunology.  He currently serves as chief operational officer and executive director of Aduro Biotech Europe, where he leads the development of new anti-cancer antibodies using the company’s proprietary B-select antibody technology.  Prior to its acquisition by Aduro in 2015, Dr. van Eenennaam served as chief operational officer of BioNovion, a company he co-founded in 2011 to focus on the development of innovative therapeutic antibodies in the field of immuno-oncology.  He is named as inventor on seven pending and granted patent families, including the patents for KEYTRUDA, and an author on over 25 publications.  Dr. van Eenennaam received his doctorate in autoimmune biochemistry (cum laude) from Radboud University Nijmegen, the Netherlands.

John Dulos, Ph.D., an immunologist with more than 20 years of experience in the pharmaceutical and biotechnology industry, is a leader in the field of immunology, oncology and infectious diseases. He currently serves as principal scientist at Aduro Biotech Europe where he oversees research and development of the company’s proprietary anti-APRIL (A PRoliferation-Inducing Ligand)-targeting monoclonal antibody, BION-1301, for the treatment of multiple myeloma. Throughout his career at multiple companies, Dr. Dulos has applied his expertise in in vitro and in vivo pharmacology of small molecules, vaccines and antibodies from preclinical development through Phase 2 clinical studies.  He is named as an inventor on two patent applications relating to KEYTRUDA and an author on 16 peer-reviewed publications, including lead authorship on a 2012 paper that first described the immune stimulating activity of KEYTRUDA (Journal of Immunotherapy 35:169-78). Dr. Dulos received his doctorate from Utrecht University in the Netherlands.

About the IPOEF Inventor of the Year Award Each year, the IPOEF recognizes outstanding recent inventions with its annual Inventor of the Year Award.  In 2016, the foundation is celebrating innovation that has led to breakthroughs in cancer treatment by honoring the inventors of six drugs in the field of immunotherapy oncology treatment, including Merck & Co.’s KEYTRUDA ® .  To learn more about the IPOEF and this award, visit www.ipoef.org .

About the Aduro - MSD Collaboration BioNovion B.V. and MSD, through a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, entered into a worldwide license agreement in 2014 for the development and commercialization of CD27 antibody agonists, and BioNovion received an up-front payment of $15 million. In 2015, BioNovion was acquired by Aduro Biotech and became its subsidiary, Aduro Biotech Europe B.V.

Under the agreement, a Joint Research Committee was formed to advance the program. Aduro has been reimbursed for certain research activities and is eligible to receive future development, commercial and net sales milestone payments. In addition, Aduro is eligible to receive royalties in the mid-single digits to low teens based on any net sales of the product, if it is approved for marketing.

About Aduro Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit  www.aduro.com .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our technology platforms, plans, and the potential for eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions.  Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates.  We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter ended September 30, 2016, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 press@aduro.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 27

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 121

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 128

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 38

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading
PostalAnnex Adds Roseville Store as Owners Reach Three

Updated Category News Views 31

A third storefront from the same operators says more than a ribbon-cutting ever will. Aarondeep Hira and Manraj Sangha have opened a PostalAnnex in Roseville, California, their third Sacramento-area location after earlier operations in Sacramento and Antelope. For a franchise system, repeat ownership is the part worth noticing. It is not a guarantee of booming sales, and...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 279

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 186

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 100

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 75

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Update: Heroes Made Joins AWS Marketplace for Schools

Updated Category News Views 120

Heroes Made's Significant Partnership with GG4L Heroes Made, a top provider of Social and Emotional Learning (SEL) solutions for students, proudly announces its incorporation into the AWS Marketplace, specifically as part of Global Grid for Learning's (GG4L) SchoolDay Collection. This progressive collaboration aims to streamline how schools access and utilize effective...

Continue Reading
Palisade Bio Secures $138 Million to Advance Clinical Programs

Updated Category News Views 173

Palisade Bio Secures Substantial Funding to Propel Clinical Trials Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company dedicated to innovating therapies for autoimmune and inflammatory diseases, recently announced the successful closing of an impressive public offering, which raised gross proceeds of approximately $138 million. This significant...

Continue Reading
Enlight's Snowflake A Project Boosts Renewable Energy Capacity

Updated Category News Views 46

Enlight Renewable Energy's New Power Purchase Agreement Enlight Renewable Energy, a noteworthy player in the renewable energy sector, recently announced exciting developments regarding its U.S. subsidiary, Clenera. They have successfully signed a power purchase agreement (PPA) with Arizona Public Service (APS) for the Snowflake A Project, which aims to bolster clean...

Continue Reading
BigBear.ai Faces Investigation Amidst Financial Restatement Concerns

Updated Category News Views 446

BigBear.ai Holdings Under Investigation BigBear.ai Holdings, Inc. (NYSE: BBAI) is currently the focus of an investigation initiated by legal representatives. This comes as a response to growing concerns among investors regarding potential inaccuracies within the company’s financial reporting. Recent disclosures made by BigBear indicate that their financial statements...

Continue Reading
Morgan Stanley's CEO Ted Pick Ascends to Chairman Role

Updated Category News Views 90

Ted Pick Takes the Helm as Chairman of Morgan Stanley In an exciting leadership development, Morgan Stanley (NYSE: MS) has named its current CEO, Edward (Ted) Pick, as the new Chairman of the Board, effective January 1, 2025. This transition comes as the firm prepares for the retirement of the current Chairman, James Gorman, who will take on the honorary title of Chairman...

Continue Reading